The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - PsiOxus Therapeutics (Inst)
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.
 
Thomas Lillie
Employment - PsiOxus Therapeutics
Leadership - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Eileen E. Parkes
No Relationships to Disclose
 
Christian Ottensmeier
No Relationships to Disclose
 
David Krige
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics (Inst)
 
Behnaz Ravanfar
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Vladimir Evilevitch
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Matthew Thomas
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Lee S. Rosen
Research Funding - Bayer (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Rgenix (Inst)